NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
3.13 (USD) • At close July 1, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.005 | 0.005 | 0.004 | 0.002 | 0.907 | 0 | 1.007 | 0 |
| Gross Profit
| 0 | -0.005 | -0.004 | -0.002 | -0.907 | 0 | -1.007 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 6.199 | 13.371 | 17.027 | 20.257 | 10.625 | 0 | 0 | 0 |
| General & Administrative Expenses
| 13.505 | 14.216 | 27.37 | 74.944 | 11.436 | 0.003 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.505 | 14.211 | 27.37 | 74.944 | 11.436 | 0.003 | 1.007 | 0 |
| Other Expenses
| 0 | 0.25 | -0.505 | -0.771 | -10.16 | 0 | 0 | 0 |
| Operating Expenses
| 19.704 | 27.582 | 44.397 | 94.43 | 11.901 | 0.713 | 0 | 0 |
| Operating Income
| -18.502 | -27.587 | -44.335 | -115.796 | -11.901 | -0.713 | -1.007 | 0 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -6.624 | -2.572 | 4.581 | 22.733 | 0.491 | 1.206 | 1.089 | -0.105 |
| Income Before Tax
| -25.126 | -30.159 | -39.754 | -93.063 | -51.777 | 0.493 | 0.082 | -0.105 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.009 | -4.581 | -21.348 | -39.43 | 0.084 | 0.016 | 0 |
| Net Income
| -25.126 | -30.15 | -39.754 | -93.063 | -51.777 | 0.408 | 0.066 | -0.105 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.39 | -3.98 | -0.6 | -7.44 | -1.51 | 0.8 | 0.074 | -0.12 |
| EPS Diluted
| -2.39 | -3.98 | -0.6 | -7.44 | -1.51 | 0.8 | 0.074 | -0.12 |
| EBITDA
| -18.502 | -30.025 | -39.75 | -93.043 | -51.719 | -0.713 | 0.082 | -0.105 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |